Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2023

Open Access 01-12-2023 | NSCLC | Review

The development of amivantamab for the treatment of non-small cell lung cancer

Authors: Danielle Brazel, Misako Nagasaka

Published in: Respiratory Research | Issue 1/2023

Login to get access

Abstract

Non-small cell lung cancer (NSCLC) patients with sensitizing oncogenic driver mutations benefit from targeted therapies. Tyrosine kinase inhibitors are highly effective against classic sensitizing epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletions and exon 21 L858R point mutations. Conversely, EGFR exon 20 insertions (exon20ins) are resistant to the traditional EGFR tyrosine kinase inhibitors (TKIs). In May 2021, the US Federal Drug Administration (FDA) provided accelerated approval to amivantamab (Rybrevant) in adults with locally advanced or metastatic NSCLC with EGFR exon20ins after treatment with platinum-based chemotherapy. Amivantamab was the first EGFR/MET bispecific antibody to be approved specifically for EGFR exon20ins where there was an unmet need. Furthermore, amivantamab is being evaluated in additional settings such as post osimertinib in sensitizing EGFR mutations as well as in MET altered NSCLC. Here we discuss amivantamab in regard to its mechanism of action, preclinical and clinical data, and clinical impact for patients with EGFR exon20ins NSCLC and beyond.
Literature
1.
Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
3.
Reck M, Rabe KF. Precision diagnosis and treatment for Advanced Non-small-cell Lung Cancer. N Engl J Med. 2017;377(9):849–61.PubMedCrossRef
4.
5.
Swanton C, Govindan R. Clinical implications of genomic discoveries in Lung Cancer. N Engl J Med. 2016;374(19):1864–73.PubMedCrossRef
6.
Sharma SV, et al. Epidermal growth factor receptor mutations in Lung cancer. Nat Rev Cancer. 2007;7(3):169–81.PubMedCrossRef
7.
8.
Kumar A, et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26(10):1742–51.PubMedCrossRef
9.
Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell Lung cancer. Biochim Biophys Acta. 2010;1804(3):559–66.PubMedCrossRef
10.
Travis WD, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.PubMedCrossRef
11.
Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell Lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–93.PubMedPubMedCentralCrossRef
12.
Sholl LM, et al. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: the Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015;10(5):768–77.PubMedPubMedCentralCrossRef
13.
Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell Lung cancer. Sem Cancer Biol. 2020;61:167–79.CrossRef
14.
Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell Lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13(1):e23–31.PubMedCrossRef
15.
Yun J, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in Diverse models of. Cancer Discov. 2020;10(8):1194–209.PubMedCrossRef
16.
Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell Lung cancer. Signal Transduct Target Therapy. 2019;4(1):5.CrossRef
17.
18.
Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008;27(1):85–94.PubMedCrossRef
19.
Zhang YW, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A. 2003;100(22):12718–23.PubMedPubMedCentralCrossRef
20.
Molnarfi N, et al. Hepatocyte growth factor: a regulator of inflammation and autoimmunity. Autoimmun Rev. 2015;14(4):293–303.PubMedCrossRef
21.
Glodde N, et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017;47(4):789–802e9.PubMedCrossRef
22.
Liu X, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011;17(22):7127–38.PubMedCrossRef
23.
Baltschukat S, et al. Capmatinib (INC280) is active against models of Non-small Cell Lung Cancer and other Cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019;25(10):3164–75.PubMedCrossRef
24.
Frampton GM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple Tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–9.PubMedCrossRef
25.
Plenker D, et al. Structural alterations of MET trigger response to MET kinase inhibition in Lung Adenocarcinoma patients. Clin Cancer Res. 2018;24(6):1337–43.PubMedCrossRef
26.
Ferguson SD, et al. Targetable Gene fusions Associate with the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018;77(6):437–42.PubMedPubMedCentralCrossRef
27.
28.
Dagogo-Jack I, et al. MET alterations are a recurring and actionable resistance mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020;26(11):2535–45.PubMedPubMedCentralCrossRef
29.
Awad MM, et al. Exon 14 mutations in Non-small-cell Lung Cancer are Associated with Advanced Age and Stage-Dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–30.PubMedCrossRef
30.
Schrock AB, et al. Characterization of 298 patients with Lung Cancer Harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493–502.PubMedCrossRef
31.
Liu X, et al. Next-generation sequencing of Pulmonary Sarcomatoid Carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802.PubMedCrossRef
32.
Saffroy R, et al. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Oncotarget. 2017;8(26):42428–37.PubMedPubMedCentralCrossRef
33.
Vuong HG, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell Lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018;123:76–82.PubMedCrossRef
34.
Drilon A, et al. Targeting MET in Lung Cancer: will expectations finally be MET? J Thorac Oncol. 2017;12(1):15–26.PubMedCrossRef
35.
Tsakonas G, et al. c-MET as a biomarker in patients with surgically resected non-small cell Lung cancer. Lung Cancer. 2019;133:69–74.PubMedCrossRef
36.
Bubendorf L, et al. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European thoracic oncology platform (ETOP) lungscape project. Lung Cancer. 2017;111:143–9.PubMedCrossRef
37.
Castiglione R, et al. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Mod Pathol. 2019;32(5):627–38.PubMedCrossRef
38.
Tong JH, et al. Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res. 2016;22(12):3048–56.PubMedCrossRef
39.
Yu HA, et al. Analysis of Tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant Lung Cancers. Clin Cancer Res. 2013;19(8):2240–7.PubMedPubMedCentralCrossRef
40.
Chabon JJ, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in Lung cancer patients. Nat Commun. 2016;7(1):11815.PubMedPubMedCentralCrossRef
41.
Ramalingam SS, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:viii740.CrossRef
42.
Caparica R, et al. Responses to Crizotinib can occur in high-level MET-Amplified Non-small Cell Lung Cancer Independent of MET exon 14 alterations. J Thorac Oncol. 2017;12(1):141–4.PubMedCrossRef
43.
Chu QS. Targeting non-small cell Lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic Lymphoma kinase fusion. Therapeutic Adv Med Oncol. 2020;12:1758835919895756.
44.
Migliore C, et al. miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. EMBO Mol Med. 2018;10(9):e8746.PubMedPubMedCentralCrossRef
45.
46.
47.
Engelman JA, et al. MET amplification leads to gefitinib resistance in Lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–43.PubMedCrossRef
48.
Bean J, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104(52):20932–7.PubMedPubMedCentralCrossRef
49.
Papadimitrakopoulou VA, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018;29:viii741.CrossRef
50.
Charakidis M, Boyer M, Targeting MET. EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell Lung cancer? Translational Lung Cancer Research. 2014;3(6):395–6.PubMedPubMedCentral
51.
Spigel DR, et al. Randomized Phase II Trial of Onartuzumab in Combination with Erlotinib in patients with Advanced non–small-cell Lung Cancer. J Clin Oncol. 2013;31(32):4105–14.PubMedPubMedCentralCrossRef
52.
Jarantow SW, et al. Impact of cell-surface Antigen expression on Target Engagement and function of an epidermal growth factor receptor נc-MET bispecific antibody *. J Biol Chem. 2015;290(41):24689–704.PubMedPubMedCentralCrossRef
53.
54.
Jo M, et al. Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal pathways in transformed cells *. J Biol Chem. 2000;275(12):8806–11.PubMedCrossRef
55.
Ortiz-Zapater E, et al. MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition. PLoS ONE. 2017;12(1):e0170798.PubMedPubMedCentralCrossRef
56.
57.
58.
Wolf J, et al. Capmatinib in MET exon 14–Mutated or MET-Amplified non–small-cell Lung Cancer. N Engl J Med. 2020;383(10):944–57.PubMedCrossRef
59.
60.
Vijayaraghavan S, et al. Amivantamab (JNJ-61186372), an fc enhanced EGFR/cMet Bispecific Antibody, induces receptor downmodulation and antitumor activity by Monocyte/Macrophage trogocytosis. Mol Cancer Ther. 2020;19(10):2044–56.PubMedCrossRef
61.
Grugan KD, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of Lung cancer cells. MAbs. 2017;9(1):114–26.PubMedCrossRef
62.
Park K, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell Lung Cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–402.PubMedPubMedCentralCrossRef
63.
Moores SL, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942–53.PubMedCrossRef
64.
Neijssen J et al. Discovery of Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem, 2021. 296.
65.
Cho BC, et al. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) Bispecific Antibody, designed to Enable multiple mechanisms of action and broad clinical applications. Clinical Lung Cancer; 2022.
66.
Minchom A, et al. Amivantamab compared with real-world therapies in patients with advanced non-small cell Lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022;168:74–82.PubMedCrossRef
67.
Chouaid C, et al. An adjusted treatment comparison comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for patients with Advanced Non-small Cell Lung Cancer with activating Epidermal Growth Factor Receptor Exon 20 insertion mutations. Adv Ther; 2023.
68.
Du X et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. The Innovation, 2021. 2(2).
69.
Haura EB, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell Lung cancer (NSCLC). American Society of Clinical Oncology; 2019.
70.
Nagasaka M, et al. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Lung Cancer. 2022;164:52–5.PubMedCrossRef
71.
Park K, et al. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023;178:166–71.PubMedCrossRef
72.
Krebs M, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: updated results from the CHRYSALIS study. J Clin Oncol. 2022;40(16suppl):9008–8.CrossRef
73.
Krebs MG, et al. Abstract CT198: subcutaneous delivery of amivantamab in patients with advanced solid malignancies: initial safety and pharmacokinetic results from the PALOMA study. Cancer Res. 2022;82(12Supplement):CT198–8.CrossRef
74.
Basse C, et al. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell Lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. Lung Cancer. 2022;173:116–23.PubMedCrossRef
75.
Belzer A et al. Spectrum of dermatologic adverse events Associated with Amivantamab Use. JAMA Dermatology, 2022.
76.
Yu D, et al. Expression profiles of Tyrosine kinases in cultured follicular papilla cells < em > Versus dermal fibroblasts. J Invest Dermatology. 2004;123(2):283–90.CrossRef
77.
Lindner G, et al. Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J. 2000;14(2):319–32.PubMedCrossRef
78.
Lacouture ME, et al. Skin toxicity evaluation protocol with Panitumumab (STEPP), a phase II, Open-Label, Randomized Trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic Colorectal Cancer. J Clin Oncol. 2010;28(8):1351–7.PubMedCrossRef
79.
Shu CA, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2. J Clin Oncol. 2022;40(16suppl):9006–6.CrossRef
80.
Robichaux JP, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell Lung cancer. Nat Med. 2018;24(5):638–46.PubMedPubMedCentralCrossRef
81.
Kim TM, et al. Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: a multicenter trial of the Korean Cancer Study Group (LU17-19). Ann Oncol. 2019;30:v628.CrossRef
82.
van Veggel B, et al. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell Lung cancer. Lung Cancer. 2020;141:9–13.PubMedCrossRef
83.
Girard N, et al. MA04.07 comparative clinical outcomes for patients with NSCLC Harboring EGFR exon 20 insertion mutations and common EGFR mutations. J Thorac Oncol. 2021;16(3):S145–6.CrossRef
84.
Ramalingam SS, et al. Overall survival with Osimertinib in untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41–50.PubMedCrossRef
85.
Zhou C, et al. OA04.03 mobocertinib in NSCLC with < em > EGFR exon 20 insertions: results from EXCLAIM and pooled platinum-pretreated patient populations. J Thorac Oncol. 2021;16(3):S108.CrossRef
86.
Cho BC, et al. 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann Oncol. 2020;31:S813.CrossRef
87.
Leighl NB, et al. 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study. Ann Oncol. 2021;32:S951–2.CrossRef
Metadata
Title
The development of amivantamab for the treatment of non-small cell lung cancer
Authors
Danielle Brazel
Misako Nagasaka
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2023
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-023-02558-4

Other articles of this Issue 1/2023

Respiratory Research 1/2023 Go to the issue

Research

Deep learning prediction of hospital readmissions for asthma and COPD

Research

Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging

Original Paper

Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong

Research

Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease: a protocolized prospective observational study

Correspondence

Early detection and stratification of lung cancer aided by a cost-effective assay targeting circulating tumor DNA (ctDNA) methylation

Research

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits